Last quarter (Q ), HTG Molecular Diagnostics's total revenue was $1.25M, a decrease of -50.37% from the same quarter last year. In Q, HTG Molecular Diagnostics's net income was $-4.52M. See HTG Molecular Diagnostics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 21	Dec 20	Dec 19	Dec 18	Dec 17
Total Revenue	$ 6.80M	$ 8.91M	$ 8.55M	$ 19.20M	$ 21.50M	$ 14.76M
Cost of Revenue	$ 3.90M	$ 4.09M	$ 3.99M	$ 8.91M	$ 5.09M	$ 4.97M
Gross Profit	$ 2.91M	$ 4.81M	$ 4.56M	$ 10.29M	$ 16.41M	$ 9.79M
Operating Expense	$ 24.12M	$ 22.64M	$ 24.14M	$ 29.25M	$ 32.57M	$ 27.51M
Operating Income	$ -21.21M	$ -17.82M	$ -19.59M	$ -18.96M	$ -16.16M	$ -17.72M
Net Non Operating Interest Income Expense	$ -884.25K	$ -1.03M	$ -770.04K	$ -334.18K	$ -186.10K	$ -1.23M
Other Income Expense	$ -198.09K	$ 1.74M	$ -500.13K	-	$ -105.06K	$ 8.00
Pretax Income	$ -22.08M	$ -17.12M	$ -20.86M	$ -19.29M	$ -16.45M	$ -18.96M
Tax Provision	$ 8.67K	$ 22.48K	$ 14.41K	$ 3.38K	$ 3.53K	$ 2.92K
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -22.09M	$ -17.15M	$ -20.87M	$ -19.30M	$ -16.45M	$ -18.96M
Basic EPS	-	-	-	-	-	-
Diluted EPS	-	-	-	-	-	-
Basic Average Shares	-	-	-	-	-	-
Diluted Average Shares	-	-	-	-	-	-
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 28.01M	$ 26.73M	$ 28.13M	$ 38.16M	$ 37.66M	$ 32.48M
Net Income From Continuing And Discontinued Operation	$ -22.09M	$ -17.15M	$ -20.87M	$ -19.30M	$ -16.45M	$ -18.96M
Normalized Income	$ -22.09M	$ -18.41M	$ -20.49M	$ -19.30M	$ -16.38M	$ -18.96M
Interest Expense	$ 955.62K	$ 1.06M	$ 1.02M	$ 957.53K	$ 901.82K	$ 1.31M
EBIT	$ -21.13M	$ -16.06M	$ -19.83M	$ -18.34M	$ -15.55M	$ -17.65M
EBITDA	$ -20.49M	$ -15.34M	$ -18.48M	$ -17.08M	$ -14.08M	$ -16.41M

Currency in USD

HTG Molecular Diagnostics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing